New drugs for childhood anemia

Related Experiment Video

Updated: Aug 30, 2026

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level
05:35

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

Published on: January 19, 2024

M La Spina1, G Russo

  • 1Regional Center of Hematology and Pediatric Oncology, University of Catania, Catania, Italy. milenalaspina@virgilio.it

Minerva Pediatrica
|November 11, 2003
PubMed

Insights

New drugs are transforming pediatric anemia treatment. This review covers erythropoietin, anti-CD20 antibodies, hemoglobin analogues, and hydroxyurea for conditions like sickle cell disease.

Area of Science:

  • Hematology
  • Pediatric Medicine
  • Pharmacology

Background:

  • The therapeutic landscape for pediatric anemia has evolved with new drug classes.
  • Recent advancements offer novel treatment strategies for various anemia types in children.

Purpose of the Study:

  • To review the latest drugs for pediatric anemia, detailing their indications, clinical utility, and challenges.
  • To provide an overview of emerging therapies in pediatric hematology.

Main Methods:

  • Literature review of recent pharmacological agents for anemia treatment.
  • Analysis of clinical data and trial outcomes for new anemia drugs.

Main Results:

  • Erythropoietin is established for anemia in chronic renal failure, prematurity, and post-transplant/chemotherapy.
  • Anti-CD20 monoclonal antibody shows efficacy in refractory autoimmune cytopenias.
  • Hemoglobin analogues are under investigation as blood transfusion alternatives.
  • Agents increasing fetal hemoglobin (HbF) are used for thalassemias and hemoglobinopathies.
  • Hydroxyurea demonstrates clinical and hematological benefits in sickle cell disease.

Conclusions:

  • New pharmacological agents have significantly altered pediatric anemia management.
  • These novel therapies offer improved outcomes for diverse pediatric hematological conditions.
  • Further research into hemoglobin analogues and HbF inducers holds promise for transfusion-dependent anemias.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...